Cancer immune-therapy company Tikcro Technologies Ltd (OTCQB:TIKRF) stated on Monday that it recorded a net loss of USD341,000 (USD0.03 per diluted share) for the second quarter ended 30 June 2018.
This is a rise in earnings when compared with a higher net loss of USD407,000 (USD0.04 per diluted share) for the same period last year.
Research and development expenses of USD188,000 and USD214,000 were recorded for Q2 2018 and Q2 2017 respectively.
As of 30 June 2018, the company announced USD5.8m in cash, cash equivalents and short-term bank deposits.
The company added that the US Food and Drug Administration (FDA) recently approved a combination treatment of a CTLA-4 antibody with a PD-1 antibody for intermediate and poor-risk patients with advanced renal cell carcinoma (RCC) and sub-types of metastatic colorectal cancer (mCRC).
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT